The global challenge
Today, memory diseases are identified too late and for too few. Traditional diagnostic pathways are often invasive, expensive, and geographically restricted, meaning millions remain locked out of the most critical window for intervention.
As a result, a massive global population is currently unable to benefit from newly developed pharmacotherapies and cutting-edge treatments that require early-stage administration to be effective.
living with dementia.
worried population
Source: Alzheimer's Disease International. Growth rates are currently accelerating due to global demographic shifts.
We are bringing an affordable digital consumer service to the market to enable earlier detection of memory impairment than today. Ennen's home-based screening can save thousands of euros in late diagnosis and delayed treatment costs by providing a window into cognitive health through a consumer device that can be used at home.
Rather than those with a diagnosis already, we serve a much larger market segment of people who are concerned about memory health. They are looking for proactive cognitive screening in an aging world. The numbers are growing – by 2050, it is estimated that there will be 150 million dementia patients.
Investment opportunity
We combine everyday well-being and clinical neuroscience. Join us in building the global standard for non-invasive cognitive screening.
Total addressable market (EU & USA).
The global market for brain health and cognitive longevity is expanding rapidly as the population ages.
Target accuracy
To prove reliable (clinical) detection results.
Target retention rate
To prove continuous use.
Current funding phase
We are looking for investors who value memory health and data-driven healthcare.
Contact CEO →